We're also continuing to invest in the platform itself. In May, we announced a strategic collaboration with ANT Neuro to co-promote their FDA-cleared neuro-navigation technology with Neurostar. Providers are looking for tools that bring more visualization, consistency, and personalization into how they plan and deliver treatment, and this partnership lets us offer that alongside the Neurostar system. We have the largest installed base of TMS systems in the country, which gives us the ability to bring innovations like this to market and scale them across the field. Moving to Greenbrook, which was the star of the quarter, the operational discipline that we've been building into the clinic business continued. Greenbrook revenue was $26.9 million, up approximately 17% year over year. Beyond the top-line growth at Greenbrook, our work on revenue cycle management continued to produce results, with cash collections growing even faster than revenue. Focusing on better qualifying patients' eligibility, cleaner claims submissions, and more efficient collections were key contributors, along with improved reimbursement rates through more effective payer contracting across both TMS and Spravato. We also began using AI in the insurance authorization process, which has helped us reduce operating costs. This reflects the operational discipline that we've been building into these clinics. And it's converting into cash, not just billings. And we believe there's still runway ahead of us. The other lever is occupancy. These clinics carry a largely fixed cost base. So the more efficiently we can run each site, and the more patients we treat, the more profitable each location becomes. That's where much of our operational focus continues to sit today. With available capacity, we're closely examining our sales methods, including number of field reps, direct-to-consumer ad spend, and peer-to-peer education events, attempting to improve referrals while doing so with the most efficient patient acquisition cost. This, too, remains a meaningful incremental profitability driver. Before we move on, I wanted to provide an update on changes to our senior leadership team. As you might imagine, I spent a fair amount of time in my first 100 days evaluating our leadership team and structure. As a result, I made some changes to our leadership team, including reducing executive headcount and flattening our structure. This should allow us to get and stay closer to the details of the business. Some of the key changes include the recent appointment of Nir Naur as Chief Financial Officer. Nir brings more than 20 years of finance experience across medical device and care delivery businesses, including at his last company, where he helped the business reach profitability and achieve positive cash flow within a year. That experience is directly relevant to our priorities at this stage of our business, and I'm confident he'll be a key thought partner as we execute on our priorities. We also promoted Corey Anderson to Executive Vice President and General Manager of Greenbrook. Cory's been with us more than five years overseeing both our technology and clinical data efforts as well as leading the commercial readiness efforts of psychedelics with our partners at Compass Pathways. Putting a dedicated leader with a rich understanding of the interventional psychiatry space as the head of Greenbrook reflects its importance to our future and the types of initiatives that will help us continue to drive growth in that part of the business. And in June, we appointed Rob Green as Senior Vice President of Sales. Rob spent his career leading commercial organizations across healthcare and medical technology, including in capital equipment and service. As we roll out new commercial models for Neurostar, Rob's experience will be central to executing that strategy. Separately, we consolidated roles in marketing and operations and Andy McCann will be stepping down as chief legal officer later this month. With this team in place, we're well positioned to execute our strategy and the priorities that we're reviewing this morning. Stepping back, we moved forward this quarter on what matters most, competing for Neurostar customers who were previously out of reach, running our Green Brook clinics more efficiently, and advancing our goals towards profitability and cash generation. With that I'll turn it over to Nir to take you through the financials and I'll come back with our outlook for the rest of the year.

Nir? Thank you Dan and good morning everyone. Let me start with a few thoughts on why I joined and then walk you through the quarter. I came to Neuronetics because I saw a business with a strong core leading technology and a national clinical network as well as a clear opportunity to improve how it converts that into profitability in cash. That is what I've spent my career doing and that is what I intend to focus on here. Enter our financials. Unless otherwise noted, all performance comparisons are being made to the second quarter of 2026 versus the second quarter of 2025. Toll revenue in the second quarter was $41.6 million, an increase of 9.1% compared to revenue of $38.1 million in the second quarter of 2025. The increase in revenue was primarily driven by higher Greenbrook revenue. With the commercial model updates that Dan mentioned in his comments, we intend to update our financial reporting on a go-forward basis to better align with the relevant operational metrics. As customers move between owning a system, financing one, purchasing support on an a a la carte basis or opting for the traditional session model, the split between capital and treatment session revenue no longer reflects the business in a consistent manner. We plan to manage the total growth of the Neurostar franchise. With a host of contributing revenue lines such as sessions, capital, lease, service, consumables and others, comparisons versus the past become less relevant for us. As a result, we will look at our Neurostar business more holistically and intend to report it as a single revenue line going forward. Accordingly, total revenue from our Neurostar business was $14.7 million in the second quarter of 2026, a decrease of 2.7%. For context, our session revenue was down double digits and our capital sales were up double digits. Greenbrook revenue was $26.9 million, a 16.8% increase. The results were driven by strong continuous provider growth and overall pricing improvement. Gross margin was 51.1% in the second quarter of 2026 compared to 46.6% in the prior year. This was a function of MIX and our improving revenue cycle management efforts. Operational expenses during the quarter were $22.7 million, a decrease of $3.1 million, or 12%, compared to $25.8 million in the second quarter of 2025. This was largely due to lower general and administrative expenses and lower sales and marketing expenses. Continued cost efficiency measures were one of the key drivers for that change. Net loss for the quarter was $3.4 million, or $0.05 per share, compared to a net loss of $10.1 million, or $0.15 per share in the prior year. Adjusted EBITDA was positive $0.3 million, as compared to negative $5.6 million in the prior year, an improvement of $5.9 million. Moving to the balance sheet and cash flow. As of June 30, total cash was $25 million, consisting of cash, cash equivalents, and restricted cash as compared to $19 million as of March 1, 2026. Cash used by operations and investing in the second quarter was $1.4 million. This compares to cash used from operations and investing of $3.8 million in Q2 of 2025. During the quarter, we also raised $7.6 million in net proceeds through our at-the-market equity offering. Now turning to guidance. We are narrowing our total revenue range to $160 to $164 million compared to prior guidance of $160 to $166 million. We now expect gross margin range to be between 48% and 50% compared to prior guidance of 47% to 49%. We're lowering our OPEX guidance to $95 to $100 million versus our prior guidance of $100 to $105 million. The majority of this change is driven by a decreased expectation of share-based compensation. Since share-based compensation fluctuates significantly, it's a non-cash component, and it's difficult to forecast, going forward, we're going to guide to OPEX excluding share-based compensation. On this basis, we would expect this number to be $91 to $96 million for the year. Our current estimate of share-based compensation is $4 million for the year. We're also updating our cash flow guidance to include both cash flow from operations and cash cash flow firm investing as we consider the sum a more representative view of the company's organic cash utilization and estimated to be in the range of negative $10.5 million to negative $14.5 million for the full year. This is compared to our prior guidance of cash flow firm operations only in the range of negative $13 million to negative $17 million. We continue to target limited net cash utilization for operations and investing in the second half of the year. In summary, this was a quarter of solid financial progress. We grew revenue, improved our margins, reduced our cash burn, and strengthened our balance sheet, all while continuing to invest in the growth of the business. Our focus is on converting that progress into sustained profitability and positive operating cash flow. With that, I will turn it back to Dan for his closing remarks.

Thanks, Nir. Let me close with a few thoughts on where we go from here. During the quarter we continued our collaboration with Compass Pathways to prepare for the anticipated commercial launch of their psychedelic therapeutic for treatment resistant depression or TRD. We also shared the stage with them at an investor panel last month to continue to educate the investor community about the potential market dynamics with a new treatment option for providers to prescribe for TRD patients. With their recent phase 3 extended durability data readout our enthusiasm for the opportunity continues to grow regulatory path the regulatory path is compass to run and I'm not going to get ahead of it but therapies like this when they come to market will require exactly the kind of delivery platform that we already operate in office drug delivery and monitoring REMS programs trained clinical staff and the benefits investigation and prior authorization infrastructure that we run every day for Spravato. As new psilocybin treatments become available, they'll need places equipped to deliver them safely and at scale. Greenberg's experience, scale, and available capacity positions us as an early leader in that space as we look forward to providing the most comprehensive menu of interventional psychiatry options for patients. More broadly, our priorities for the rest of the year are clear. We'll continue expanding how we compete within the TMS space with Neurostar, keep driving operational discipline and cash generation at Greenbrook while seeking to help even more patients, expanding our occupancy, and positioning ourselves for the opportunities ahead in interventional psychiatry. Ultimately, we intend to be the destination of choice for the psychiatry community looking for the most effective treatment interventions for their patients. We have real work in front of us, but we have the team, the resources, and the momentum to see it through. Before I close, I'll note that earlier this month we announced a constructive understanding with one of largest shareholders, reflecting a shared commitment to maximizing long-term value for our shareholders. The Board and I welcome that alignment and it reinforces the focus we all share on executing the priorities I've laid out this morning. I want to thank our employees for a hard-fought quarter and for the work that they do every day on behalf of the patients that we serve and our shareholders for their continued support. With that operator, we're ready to open the line for questions.

Thank you. Ladies and gentlemen, as I wanted to ask a question at this time, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, simply press star one one again. Please stand by while we compile the Q&A roster. Now, first question coming from the line of Bill Povonek with Canaccord. The line is now open.

Hey, great. Thanks. Good morning. Can you hear me okay?

Yep. Good morning, Bill.

Good morning. First of all, congratulations on a solid quarter, you know, definitely improving the cash flow. I'm going to focus on the future rather than the past. In terms of Greenbrook, you know, as you're leaning into this really service offering for all these new psychedelics coming to market, I was wondering if you could help us understand just with the Greenbrook footprint, you know, as you go to optimize those. One, like how many rooms are typically available on average per site? Two, you know, as you become more cash generating, could we expect you to start opening more facilities or expanding the existing facilities? You know, my understanding is the Compass product is like a six hour versus maybe Spravato with about two hours of observation. So I'm trying to, you know, as new drugs come to market, they're going to have different requirements and how do you address those capacity issues and balance that against revenue? But really, it's on the green brook and just leaning in there.

Yeah, good question. Thanks, Bill. So I think, first of all, I'll talk about psychedelics in a minute, but I think that initially there's a lot of runway that continues to be available to us simply in improving the capacity that's available within so many of our sites. So we've got a fair amount of fixed costs, as you know, and we've talked about having available capacity as much as 40% that's still not consumed. So filling those chairs with patients that can benefit from our therapies is a top priority, and I think we have a lot of improvement to occur even while we're waiting for the psychedelics to be introduced. That said, we think about it more as, you know, units of time and available capacity. A lot of these rooms where we treat patients for Spravato can quite easily be converted to also administer psychedelics like Compass 360. So I think that we've already got the capacity in the rooms, and it's a matter of making sure that we're filling these to better capacity, which is an opportunity for growth that we have even before some of the psychedelics come available. And then as they do, we have been putting a lot of energy into making sure that we're being thoughtful about how we would schedule those varying treatments. As we know, TMS is a matter of minutes. It's a couple of hours for Spravato, and to your point, probably closer to six hours for Compass 360 in varying sequences for some of the other therapeutics to come later. We're starting to use AI for scheduling to optimize how we can make sure that we do that in the most productive way. So I think there's a lot of opportunity for us to continue to fill that capacity. And once we do, once we start to get closer to that and we need more space, certainly more sites or expanding those footprints is well within our roadmap. But initially, I think there's so much unused capacity, we're really focused there first, and then sequentially there will be an opportunity for us to look at expansion.

Excellent. If I could have one follow-up. Just on, you know, you've come in and you've made a lot of, you've cut a lot of costs. I mean, definitely have improved the operating structure of the business um you know if you think of that mission from here forward with the recent announcements you've made and the changes in management you know are you through kind of the bulk of the the changes and here it's more incremental tweaking from a cost structure or just how should we think about the opportunity the for further efficiency gains in the operating structure thanks yeah I think that you know a natural thing is sometimes we don't always look in the mirror first as executives so starting with the leadership ranks and trying to make sure that the structure and the people that fill the right roles was

established I feel really good about where we sit today I think we've added some really good talent I think we've redistributed some of the assignments to some really talented up-and-coming folks within the organization so I think that we I feel like we sit quite well there I think there's probably still opportunities for us I think this is where having a new CFO flanking me with just a couple of weeks under his belt he and I will have an opportunity to more comprehensively continue to examine where those additional opportunities might exist but but organizationally I feel like we've made a lot of progress and i'm feeling very good about kind of how we've anchored ourselves at this point great thank you

thanks bill thank you our next question in queue coming from the lineup danny southwood citizens bank your line is now open yeah great thank you for the questions um really nice quarter and near congrats on the new role and it's it's great to have you on the call Just on my first one, I want to make sure I'm kind of understanding the Neurostar treatment session dynamic here. So it sounds like the normalization of inventory should continue through the rest of the year or so, should continue to be down maybe with some offset from gains in capital. So I just want to make sure that's the right way to be thinking about it.

And then do you think this is more of a dynamic for just new customers or do you expect, you know, a larger portion of your existing customers to transition to some of these other models and offerings that you have thank you yeah thanks Danny could appreciate the question I think on the sessions inventory just to be clear we feel like that the inventories are down about as low as we would expect them to be maintained so I don't see any continued inventory reductions in the back half of the year I think we've after the second quarter I think largely equilibrated to where we think normal sustainable inventories would be so I don't see that as a as much of a headwind in the back half as perhaps in the second quarter I think from an existing customer standpoint one of the things I want to make sure doesn't get lost is a comment I made in the prepared remarks we we know that our chairs receive almost twice as much velocity patient velocity as the competitive landscape so we certainly think that a lot of the customers that have selected us did so largely because of the comprehensive support we provide and the kind of improvements it makes in their own practice so I think that we expect that you know an awful I think the majority probably of those sessions customers who have benefited from that level of comprehensive service will continue in that vein. We will certainly offer more options, and that's what we've been talking about in our new go-to-market strategy is we want to let the customer decide where they see the value and how they want to pay for it. So I think the other point to be made is that if a customer, a new customer, for example, chose the capital route versus the traditional sessions route, they'll still pay for things like service and consumables and training, and those things are currently embedded in the sessions structure, and it's one of the reasons that we chose to start to report on this on a more holistic basis, because there's probably going to be some noise moving back and forth, and I think that it's important to appreciate that some of the consumables, some of the service that revenue that we've gotten has been embedded in the sessions revenue side so you know we're going to give customers the option to decide how they want to pay for the value that we bring but ultimately I think that while we will expect to open ourselves up to new socket placements with this broader go-to-market we're also hearing that there's a big segment of our customer base that remind us why they picked us in the first place, and that's that comprehensive support that we provide.

That's great. I appreciate that. And then this one quick follow-up for me. It's great to see the improvement on operating expenses and below the top line. I wanted to focus on gross margin. That line was really strong, even with clinic revenue being the primary driver of growth and making up a larger mix of sales. So could you just give us a little bit more color on what drove that gross margin expansion I think you called out some pricing improvement within clinics. So any color there or just anything else on the execution would be great.

Yeah, that's certainly a high point for the quarter. And as you know, we raised our guidance on gross margin for the full year. So we think that some of these improvements are durable. And the good news, I think, also is that we saw support or strength in the gross margin on both the Greenbrook and the Neurostar side. So on the Greenbrook side, a lot of it has to do with improved revenue cycle management, and that is as we make sure that we're being more disciplined about patient qualification, which is good for the patient as well. They don't want to find out that they don't meet the right criteria when they're three sessions in. so that's been a focus that leads to cleaner claims and more efficient accounts receivable so all of those things mean you capture a bit better revenue on a bill dollar than we did in the past and I think those are durable and those are clearly things that are contributing to the better gross margin on Greenbrook along with some pricing relative to our team's work with some of the third-party payers. On the Neurostar side, while Sessions revenue was off a bit and capital was up, I think it also points to the fact that as our mix starts to equilibrate more and it's not exclusively on the Sessions side, our ASP is going up. So as that growth occurs in capital, I think that that can be also a sustainable good guy for us on the gross margin side and of course both of those considerations are embedded in our updated guidance great thank you so much for the questions thank you thank you and the final question comes from the line of sam hyper with bti gel and is now open hi good morning thanks for taking the questions here um maybe i can start on the greenbrook side a really strong quarter on that side of the business.

Dan, I'm wondering if you could help parse out maybe some of the underlying trends you're seeing on the Spravato side versus the TMS side of the business. And then, you know, just as I think about Compass and Psilocybin entering the market, you know, perhaps next year, maybe just talk about how, you know, your model is set up best by offering, you know, Spravato, TMS, Psilocybin, and why that's the best model for Yeah.

Making a quick note here. So I think, first of all, on the Spravado versus TMS, we saw a bit more strength probably from Spravado even than TMS, but I think the fact that the overall business is growing is just a good reflection of the fact that Greenbrook's becoming an increasing destination of choice for referral sources. The Spravato business is certainly more durable, as I think I've alluded to in the past. The duration between treatments, even after an initial round, continues to be more sustainable. I guess that's good for us from a patient standpoint. It means they have to revisit us a bit more frequently. So those patients tend to stay more active for a longer period of time within our network. I think on the compass side you know I think there's a number of things that I alluded to in our comments earlier that really position us well I think we're really poised to be a first mover benefactor just in part because of the close collaboration we've had with them in some of the preparation benefits but also the infrastructure that we talked about that's already exists because of our Spravato participation. The REMS certification, the rooms setups, the capacity availability, all of those things I think lend themselves to positioning us in kind of a pole position. And I think the other one, Sam, is a little bit about kind of your question about the blend. We really want to position ourselves with referral sources as the destination of choice for whatever intervention is best suited for that patient within the interventional psychiatry scope. And I think that we've already done that with TMS, with Spravato. We look forward to doing it with Compass. And I think as additional new therapeutics come out, we are positioning ourselves both infrastructure and on brand that we really want to be the destination that they can entrust their patients. The fact that we don't do medical management and psychotherapy also gives those referral sources the confidence that they can send their patients to us and know that they'll get them back. And I think all of those are important parts of kind of the ecosystem we're trying to build.

Yeah, that's really helpful, Dan. Thanks for the added color there. Maybe I can just use a follow-up here on some of the comments around different sales methods you're going to be evaluating with regard to field reps and direct-to-consumer spending. Are there certain KPIs that you'll be tracking or that we should be mindful of as you, I guess, evaluate efficiently getting more patients through the door here?

Yeah, I think, so externally, KPIs, I think you can ultimately look at our operating expenses, of course. Internally, patient acquisition cost is one that we're taking a more scrutinizing look at and I can say quite confidently that the account managers that support the Greenbrook community are proving to be a very effective source for referral generation. I think we want to take a closer look at the balance and spend between our field team and some of our direct-to-consumer ad spend along with some of the other things that we do from a peer-to-peer education, and we're just trying to be a lot more thoughtful about trying to evaluate what is it, what each one of us of those cost, and what, which ones are returning the most effectively. And, you know, I would expect that we will probably, you know, pull and push on some levers, try and rebalance our spend in the most effective paths and at the expense of some of the others. So some of that work continues to go on. There's a lot of analytics that we're working on, but at the end of the day, I think it really comes down to our patient acquisition costs and what's the most efficient way to get the right patient who can benefit from our therapies in a chair.

Okay, very good. Thanks for taking the questions.

Thank you. Now I'm showing up for the questions in the queue. I will now turn the call back over to Mr. Dan Reavers for any closing comments.

Thanks, Operator, and thank you to everyone for joining today's call. We really look forward to updating you on our progress during our next quarterly call and hope everybody has a good rest of the summer.

This concludes today's conference call. Thank you for your participation.